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INTRODUCTION
Cytarabine (cytosine arabinoside, Ara-C) is an antimetabolite analogue of cytidine that is used as a chemotherapeutic agent for the treatment of acute myelogenous
leukemia and lymphocytic leukemias 1 . The most
common side effects of this therapy include myelosuppression, pancytopenia, hepatotoxicity, gastrointestinal
ulceration with bleeding, and pulmonary infiltrates 2 .
Cardio-pulmonary complications of cytarabine therapy
are uncommon, but include supraventricular and
ventricular arrhythmias, sinus bradycardia, and recurrent
heart failure 2, 3 . Occasionally, patients may develop
pericarditis leading to pericardial tamponade, which can
be fatal. We report a case of cytarabine-induced
pericarditis and pericardial effusion to increase awareness
about this serious side effect of cytarabine and review
the current literature.

CASE PRESENTATION
A 44-year-old male with hypertension, obstructive sleep
apnea, stage 3 chronic kidney disease, and recent
admissions for symptomatic anemia of unknown
etiology presented to the hospital after his outpatient
lab work revealed a leukocytosis of 75,000 cells/µl,
thrombocytopenia of 117,000 platelets/ µl, and anemia
with hemoglobin of 6.4 g/dl. An inpatient bone marrow
biopsy revealed acute myeloid leukemia. A baseline
transthoracic echocardiogram was obtained in preparation

for inpatient chemotherapy, and demonstrated mild
global left ventricular dysfunction with ejection fraction
of 40%. The cardiomyopathy was attributed to his
underlying hypertension or sleep apnea, and not
coronary artery disease based on a normal coronary
computed tomography (CT) angiogram. The patient
was started on induction therapy with high-dose
cytarabine therapy at 3g/m2 every twelve hours without
an anthracycline agent such as doxorubicin.
On day 5 of cytarabine therapy, the patient developed
non-radiating sharp chest pain that worsened with
inspiration and palpation. He had no cough or sputum
production. His cardiac exam revealed a tri-phasic,
high-pitched friction rub best heard over the left lower
sternal border. He was normotensive, did not have pulsus
paradoxus, and had minimally distended jugular veins.
An electrocardiogram revealed widespread concave
ST-elevation and PR-depression in the limb leads (I, II, III,
avF) and precordial leads (V5-V6) concerning for acute
pericarditis (Figure 1). The patient also had an elevated
troponin T to 0.07 ng/ml (normal <0.01) and an elevated
pro-BNP of 2080 pg/ml (normal <125) in the setting of
acute on chronic kidney disease. A limited transthoracic
echocardiogram revealed a small-to -moderate
pericardial effusion along the inferolateral and inferior
aspects of the left ventricle (Figure 2). There was no
evidence of pleuritis on chest x-ray or chest CT. The
patient was transferred to the cardiac intensive care unit
for further management.

Figure 1. A 12-lead electroc a rd i o g r a m s h ow i n g
ST-segment elevations
(black arrow) and
PR-depressions (blue
arrow) in multiple leads,
consistent with pericarditis.
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Figure 2a. A transthoracic 2-dimensional echocardiogram (parasternal long-axis
view) showing a posterior pericardial effusion (PPE). LV, left ventricle; RV, right
ventricle; LA, left atrium; Ao, aorta.

Figure 2b. A transthoracic 2-dimensional echocardiogram (apical 4-chamber view)
showing a circumferential pericardial effusion (PE). LV, left ventricle; RV, right
ventricle; LA, left atrium; RA, right atrium.

DIFFERENTIAL DIAGNOSIS

as neutropenic fever. Due to the acute renal failure,
colchicine was not initiated. In addition, his severe
thrombocytopenia limited use of aspirin and nonsteroidal
anti-inflammatory drug (NSAID). Steroid therapy was
discussed, but given the stability of the patient and the
lack of strong evidence supporting steroid therapy,
watchful management was chosen. Daily transthoracic
echocardiograms revealed stable pericardial effusions.
Cytarabine was never restarted. The patient eventually
died after a prolonged and complicated hospitalization
with renal failure requiring hemodialysis, septic thrombophlebitis with bilateral internal jugular clots, and fungemia.
Of note, the fungemia developed over a week after the
pericarditis; and it was felt to be from the hemodialysis
catheter that was placed after the pericarditis occurred.
An autopsy was not performed.

When pericarditis is complicated by a pericardial effusion,
a pericardiocentesis is often recommended to relieve
pressure and to rule out infectious etiologies (viral,
bacterial, tuberculosis, fungal), leukemic involvement, and
pericardial hemorrhage. Since our patient’s pericardial
effusion was only small-to-moderate in size without
evidence of tamponade, and he had a high bleeding risk
from thrombocytopenia, a pericardiocentesis was not
performed. The absence of pericardial cultures and
cytology made it challenging to definitively rule out other
causes. However, he was naïve to radiation therapy and
the patient’s infectious work up (blood and urine cultures;
CT of the chest, abdomen, and pelvis; and cytomegalovirus serology) was unrevealing. Although he had acute
kidney injury, his blood urea nitrogen was only mildly
elevated at 33 mg/dL with a creatinine of 1.8 mg/dl
(baseline unknown, but was 1.4 on admission).
Rheumatological labs were not checked, but clinically,
the patient did not show evidence of autoimmune disease
given the absence of myalgia, arthralgia, skin or nail
changes, or any evidence of an underlying vasculitis or
serositis. Although it is possible that leukemic infiltration of
the pericardium was the cause of the pericardial effusion,
leukemic infiltration of the pericardium is very rare 3 .
Ultimately, the temporal relationship bet ween
chemotherapy and the onset of pericarditis, as well as the
absence of other potential etiologies, suggest that
cytarabine was the most likely cause of this patient's
presentation.

OUTCOME AND FOLLOW UP
The patient’s hospitalization prior to his episode of chest
pain had been complicated by acute renal failure attributed
to acute tubular necrosis or cardiorenal syndrome as well

DISCUSSION
Our patient developed pericarditis and pericardial
effusions after 10 doses of high dose cytarabine. The
incidence of cytarabine-induced pericarditis is unknown,
although there are at least nine published reports of
cytarabine-induced pericarditis in the literature 3-11 . In
addition, the manufacturer’s (Upjohn) database reported
six cases of pericarditis following initiation of cytarabine
therapy3 .
The pathogenesis behind cytarabine-induced pericarditis
is unclear, but some believe it is secondary to endothelial
damage by cytarabine12, 13 . Chiche et al. found elevated
levels of TNF-alpha and platelet activating factor after
cytarabine therapy, suggesting that cytarabine-related
pericarditis may be caused by a systemic inflammatory
state amenable to steroid therapy14 . Others suggest an
immunologic pathogenesis of delayed hypersensitivity
reaction since cytarabine-associated pericarditis often
occurs after repeat administration of the drug3,4.
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The onset of cytarabine-induced pericarditis varies
between 3 to 29 days following initiation of cytarabine
therapy3-11 . Treatment of cytarabine-induced pericarditis
has not been adequately studied. NSAIDs may be helpful,
but are often contraindicated in patients with hematologic
malignancy due to their severe thrombocytopenia.
Several authors have recommended steroid use 4,6,8 ,
although there have been no studies to determine the
dose, route, or duration. Our patient’s pericarditis
remained stable without any medications. However, after
reviewing the literature and understanding the likely
pathogenic mechanism behind cytarabine-induced
pericarditis, in future cases we would suggest treatment
with high-dose steroids for cytarabine-induced pericarditis
cases especially when NSAIDs are contraindicated and
the patient is unstable.		
Recurrence of pericarditis after cytarabine-induced
pericarditis has not been formally studied, but a case
report by Reykdal et al. discusses a patient who developed
pericarditis on two occasions after cytarabine use (day 5
and 14) 3 . In addition, Patel et al. noted that 10-30% of
patients with acute pericarditis from any cause have
recurrent disease11 . Therefore, patients with a history of
pericarditis may be at an increased risk of developing
pericarditis from cytarabine, and patients who have
developed cytarabine-induced pericarditis should be
monitored very closely for recurrence if cytarabine is used
again.
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KEY POINTS
Our case illustrates a presentation of cytarabine-induced
pericarditis and pericardial effusion, which is a rare but
serious complication of cytarabine. Pericardial effusion
can lead to potentially fatal tamponade, so a high index of
suspicion is necessary for any patient receiving cytarabine,
especially if they develop chest pain. Treatment with
high-dose steroids should be initiated early with pericardiocentesis, if necessary. However, in patients with milder
symptoms and lack of hemodynamic compromise,
watchful waiting while delaying treatment can be a
reasonable and safe option.
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